The cool thing that's happening right now, maybe this is small, maybe I'm over hyping this, but if you want to go look at Bitcoin in the Bloomberg terminals, the pricing chart on the right side, like the graph where you see the prices, the little tick marks, they are denominated in millions of dollars. So right now on the price of a Bitcoin, according to Bloomberg, when you go up and open up Bloomberg, you see a Bitcoin price of 0.112% million, not $112,000 or whatever. You see it denominated in millions of ...

[Music] Thanks for coming to my talk. I'm Shazage. Uh I'm one of the co-founders at Orb.Um and I'm going to be talking about how to think about pricing. Um maybe top level takeaway uh from this talk is that pricing is a is a deep complicated topic. We're going to cover some examples. We're going to cover some tactical advice.Um, but in general, the way you should think about pricing is pricing is a form of friction uh for your product and sometimes that friction can be applied for very good reason. Sometime ...

Johnson & Johnson (JNJ) 2025 Conference Summary Industry Overview - The healthcare industry is currently facing unprecedented challenges related to tariffs and policy changes, impacting growth expectations for many companies [3][4] - Johnson & Johnson is committed to investing $55 billion over the next four years, representing a 25% increase, primarily influenced by tax policy changes [8] Key Financial Insights - In Q1, Johnson & Johnson absorbed an estimated $400 million impact from tariffs, primarily affecting the med tech segment, but this impact has since been reduced to approximately $200 million due to changes in the tariff landscape [5][6] - The company reported a 4% growth in Q1 despite losing a significant product, Stellar, which had a $10 billion market value [27] Innovative Medicine Segment - Johnson & Johnson's innovative medicine segment is projected to grow at a CAGR of 5-7% from 2025 to 2030, driven by transformative drugs [30][34] - Key products include: - Tremfya for psoriasis, projected to generate $4 billion by 2027-2028, with expectations of 25% higher sales than market estimates [23][24] - Ribrovant for lung cancer, anticipated to exceed $2 billion in the same timeframe, with potential for improved patient outcomes [24] - New oral formulation for psoriasis, expected to file for approval later this year [25] - A promising bladder cancer treatment projected to significantly outperform analyst expectations [26] Med Tech Segment - The med tech segment is also expected to grow at a CAGR of 5-7% from 2023 to 2028, although current performance is not meeting expectations [34] - Key developments include: - Progress in wound closure and biosurgery, with advancements in the OTAVA robotic surgical solution [35] - Strong uptake of the Vellus knee solution, with expectations for mid-single-digit growth in orthopedics [36] - Continued leadership in vision care, with plans to reinvigorate growth through commercial efforts [38] - Challenges in electrophysiology (EP) due to increased competition and regulatory pauses, but efforts are underway to regain market position [39][42] Pricing and Access Issues - Johnson & Johnson's average net price has decreased by 3-4% annually over the past six years, limiting pricing power [22] - The company emphasizes the need for discounts and rebates to reach patients effectively, with an average discount of 55-60% off list prices in the U.S. [14][15] - Access to oncology drugs in the U.S. is significantly higher than in other G20 countries, highlighting the importance of maintaining access to innovative treatments [16] Litigation and Financial Management - The company has reversed a $7 billion accrual related to talc litigation, expressing confidence in its legal position and financial stability [49][52] - Johnson & Johnson generates $20 billion in free cash flow, allowing for continued investment in R&D and acquisitions despite litigation risks [52] Investor Outlook - Johnson & Johnson is positioned as a reliable investment with significant growth potential in the second half of the decade, despite current headwinds [55] - The company is focused on delivering sophisticated treatments and maintaining investor returns [55]

Core Insights - The report provides detailed insights into the global and regional market trends of Tributyl Phosphate from 2019 to 2024, with forecasts extending to 2029, covering various aspects such as chemical structure, safety, handling, toxicology, and transport data [1][2][3] Market Overview - The study explores manufacturing methods, patents, key applications, and end-use sectors, analyzing market drivers, challenges, supply-demand dynamics, and pricing across different regions including Europe, Asia, and North America [1][4][5] - It serves as a critical resource for understanding the Tributyl Phosphate industry and its growth potential worldwide [1][3] Applications and Manufacturing - The report examines various applications of Tributyl Phosphate and analyzes relevant manufacturing methods, supported by a review of patents [4][10] - It provides insights into the end-use sectors for Tributyl Phosphate, highlighting its significance in different industries [5][10] Market Dynamics - The report covers market drivers, challenges, and opportunities from 2019 to 2024, along with supply and demand dynamics [12] - It includes a comprehensive analysis of market prices across different regions and evaluates future trends and supply-demand scenarios up to 2029 [5][11] Key Topics Covered - General information, synonyms, chemical composition, safety, hazards, handling, storage, toxicological and ecological details, and transport information are included [10][11] - The report addresses key questions regarding market trends, size, main players, and future development drivers and challenges [10][11]